Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.

Kidney & blood pressure research - 1 Jan 2006

Park Hyeong Cheon, Choi Hoon Young, Kim Beom Seok, Kang Shin Wook, Choi Kyu Hun, Ha Sung Kyu, Lee Ho Yung, Han Dae Suk

Abstract excerpt

BACKGROUND: The antiproteinuric effect of angiotensin-converting enzyme (ACE) inhibitors appears to vary depending on the ACE insertion (I)/deletion (D) genotype in non-diabetic nephropathy. This interaction may be overcome by using an angiotensin II receptor blocker. We evaluated the short-term...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Blood Pressure
Share to Diuretics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Gene Deletion

Share to Losartan

Share to Peptidyl-Dipeptidase A

Share to Proteinuria

Source

Identifiers

PMID: 16960460
DOI: 10.1159/000095736

Genes

ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16960460-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.PMID 16960460Read ↗

Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?Semantic proximity Read ↗

Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?Semantic proximity Read ↗

ACE insertion/deletion polymorphism and diabetic nephropathy: clinical implications of genetic information.Semantic proximity Read ↗

Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.Semantic proximity Read ↗

Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.Semantic proximity Read ↗

Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.Semantic proximity Read ↗

The impact of angiotensin converting enzyme insertion/deletion gene polymorphism on diabetic kidney disease: A debatable issue.Semantic proximity Read ↗

The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan.Semantic proximity Read ↗

ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With NephropathySemantic proximity Read ↗

ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus.Semantic proximity Read ↗

Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.Semantic proximity Read ↗

Different Mechanisms for the Progression of CKD with ACE Gene Polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.